Verrica Pharmaceuticals

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$12,702
$3,439
$344
$-1,781
Gross Profit
12,362
3,016
-281
-2,216
EBITDA
2,534
-8,130
-13,600
-20,142
EBIT
2,335
-8,338
-13,853
-20,484
Net Income
204
-9,742
-16,202
-22,860
Net Change In Cash
12,702
3,439
344
-1,781
Free Cash Flow
-10,044
-12,677
-16,064
-8,574
Cash
15,396
29,595
46,329
22,959
Basic Shares
9,490
9,483
6,732
4,680

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$7,566
$5,124
$9,032
$12,000
Gross Profit
5,713
4,378
8,307
11,528
EBITDA
-65,898
-62,197
-21,597
-30,313
EBIT
-67,167
-63,033
-22,315
-30,785
Net Income
-76,579
-66,995
-24,487
-35,080
Net Change In Cash
7,566
5,124
9,032
12,000
Cost of Revenue
18,521
5,066
Free Cash Flow
-60,954
-38,939
-18,952
-28,465
Cash
46,329
69,547
34,273
15,752
Basic Shares
5,180
4,534
3,416
2,704

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
$0.02
2025-03-31
-$0.10
2024-12-31
-$0.20